Literature DB >> 34274511

North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Justin R Boike1, Bartley G Thornburg2, Sumeet K Asrani3, Michael B Fallon4, Brett E Fortune5, Manhal J Izzy6, Elizabeth C Verna7, Juan G Abraldes8, Andrew S Allegretti9, Jasmohan S Bajaj10, Scott W Biggins11, Michael D Darcy12, Maryjane A Farr13, Khashayar Farsad14, Guadalupe Garcia-Tsao15, Shelley A Hall16, Caroline C Jadlowiec17, Michael J Krowka18, Jeanne Laberge19, Edward W Lee20, David C Mulligan21, Mitra K Nadim22, Patrick G Northup23, Riad Salem2, Joseph J Shatzel24, Cathryn J Shaw25, Douglas A Simonetto26, Jonathan Susman27, K Pallav Kolli19, Lisa B VanWagner28.   

Abstract

Complications of portal hypertension, including ascites, gastrointestinal bleeding, hepatic hydrothorax, and hepatic encephalopathy, are associated with significant morbidity and mortality. Despite few high-quality randomized controlled trials to guide therapeutic decisions, transjugular intrahepatic portosystemic shunt (TIPS) creation has emerged as a crucial therapeutic option to treat complications of portal hypertension. In North America, the decision to perform TIPS involves gastroenterologists, hepatologists, and interventional radiologists, but TIPS creation is performed by interventional radiologists. This is in contrast to other parts of the world where TIPS creation is performed primarily by hepatologists. Thus, the successful use of TIPS in North America is dependent on a multidisciplinary approach and technical expertise, so as to optimize outcomes. Recently, new procedural techniques, TIPS stent technology, and indications for TIPS have emerged. As a result, practices and outcomes vary greatly across institutions and significant knowledge gaps exist. In this consensus statement, the Advancing Liver Therapeutic Approaches group critically reviews the application of TIPS in the management of portal hypertension. Advancing Liver Therapeutic Approaches convened a multidisciplinary group of North American experts from hepatology, interventional radiology, transplant surgery, nephrology, cardiology, pulmonology, and hematology to critically review existing literature and develop practice-based recommendations for the use of TIPS in patients with any cause of portal hypertension in terms of candidate selection, procedural best practices and, post-TIPS management; and to develop areas of consensus for TIPS indications and the prevention of complications. Finally, future research directions are identified related to TIPS for the management of portal hypertension.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ascites; Cirrhosis; Complications; Consensus Statement; End-Stage Liver Disease; Guidance Document; TIPS Procedure; Variceal Bleeding

Mesh:

Year:  2021        PMID: 34274511      PMCID: PMC8760361          DOI: 10.1016/j.cgh.2021.07.018

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   13.576


  219 in total

1.  Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS).

Authors:  Manuela Merli; Valentina Valeriano; Stefania Funaro; Adolfo Francesco Attili; Andrea Masini; Cesare Efrati; Castro Stefano De; Oliviero Riggio
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

Review 2.  Review article: renal function assessment in cirrhosis - difficulties and alternative measurements.

Authors:  E Cholongitas; V Shusang; L Marelli; D Nair; M Thomas; D Patch; A Burns; P Sweny; A K Burroughs
Journal:  Aliment Pharmacol Ther       Date:  2007-10-01       Impact factor: 8.171

Review 3.  Hepatorenal syndrome: pathophysiology and management.

Authors:  Hani M Wadei; Martin L Mai; Nasimul Ahsan; Thomas A Gonwa
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-12       Impact factor: 8.237

4.  Transjugular intrahepatic portosystemic shunt before abdominal surgery in cirrhotic patients: a retrospective, comparative study.

Authors:  Evelyne Vinet; Pierre Perreault; Louis Bouchard; Denis Bernard; Ramses Wassef; Carole Richard; Richard Létourneau; Gilles Pomier-Layrargues
Journal:  Can J Gastroenterol       Date:  2006-06       Impact factor: 3.522

5.  Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters.

Authors:  J Quiroga; B Sangro; M Núñez; I Bilbao; J Longo; L García-Villarreal; J M Zozaya; M Betés; J I Herrero; J Prieto
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

6.  Effect of transjugular intrahepatic portosystemic shunt placement on renal function: a 7-year, single-center experience.

Authors:  Curtis L Anderson; Wael E A Saad; Sean D Kalagher; Steven Caldwell; Saher Sabri; Ulku C Turba; Alan H Matsumoto; John F Angle
Journal:  J Vasc Interv Radiol       Date:  2010-08-05       Impact factor: 3.464

7.  Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding.

Authors:  Alberto Monescillo; Francisco Martínez-Lagares; Luis Ruiz-del-Arbol; Angel Sierra; Clemencia Guevara; Elena Jiménez; José Miguel Marrero; Enrique Buceta; Juan Sánchez; Ana Castellot; Mónica Peñate; Ana Cruz; Elena Peña
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

8.  Budd-Chiari syndrome: long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt.

Authors:  Alexandra Zahn; Daniel Gotthardt; Karl Heinz Weiss; Götz Richter; Jan Schmidt; Wolfgang Stremmel; Peter Sauer
Journal:  BMC Gastroenterol       Date:  2010-03-01       Impact factor: 3.067

9.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

Authors:  Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

10.  Short outcome comparison of elderly patients versus nonelderly patients treated with transjugular intrahepatic portosystemic stent shunt: A propensity score matched cohort study.

Authors:  Yang Li; Fengyan Wang; Xiaomei Chen; Bin Li; Wei Meng; Chengyong Qin
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

View more
  6 in total

Review 1.  Recent updates in preemptive transjugular intrahepatic portosystemic shunt for acute variceal bleeding.

Authors:  James H Helzberg; Jacqueline B Henson; Andrew J Muir
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-09-26

Review 2.  4D Flow MRI in the portal venous system: imaging and analysis methods, and clinical applications.

Authors:  Ryota Hyodo; Yasuo Takehara; Shinji Naganawa
Journal:  Radiol Med       Date:  2022-09-19       Impact factor: 6.313

3.  In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample.

Authors:  Wisit Kaewput; Charat Thongprayoon; Carissa Y Dumancas; Swetha R Kanduri; Karthik Kovvuru; Chalermrat Kaewput; Pattharawin Pattharanitima; Tananchai Petnak; Ploypin Lertjitbanjong; Boonphiphop Boonpheng; Karn Wijarnpreecha; Jose L Zabala Genovez; Saraschandra Vallabhajosyula; Caroline C Jadlowiec; Fawad Qureshi; Wisit Cheungpasitporn
Journal:  World J Gastroenterol       Date:  2021-12-07       Impact factor: 5.742

4.  Influence of different portal vein branches on hepatic encephalopathy during intrahepatic portal shunt via jugular vein.

Authors:  Xin Yao; Sheng He; Meng Wei; Jian-Ping Qin
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

Review 5.  The Portosystemic Shunt for the Control of Variceal Bleeding in Cirrhotic Patients: Past and Present.

Authors:  Petre Radu; Virgiliu-Mihail Prunoiu; Victor Strâmbu; Dragos Garofil; Roxana Elena Doncu; Eugen Brătucu; Laurentiu Simion; Maria-Manuela Răvaş; Mircea Nicolae Brătucu
Journal:  Can J Gastroenterol Hepatol       Date:  2022-09-17

6.  Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress.

Authors:  Yang Tai; Chong Zhao; Linhao Zhang; Shihang Tang; Xintong Jia; Huan Tong; Rui Liu; Chengwei Tang; Jinhang Gao
Journal:  J Cell Mol Med       Date:  2021-10-05       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.